...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Radiotherapy and oncology: Journal of the European Society for Therapeutic Radiology and Oncology >Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer: Early late toxicity and 3-year clinical outcome
【24h】

Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer: Early late toxicity and 3-year clinical outcome

机译：超分割强度调制弧光疗法治疗淋巴结转移性前列腺癌：早期晚期毒性和3年临床疗效

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background and purpose For patients with N1 prostate cancer (PCa) aggressive local therapies can be advocated. We evaluated clinical outcome, gastro-intestinal (GI) and genito-urinary (GU) toxicity after intensity modulated arc radiotherapy (IMAT) + androgen deprivation (AD) for N1 PCa. Material and methods Eighty patients with T1-4N1M0 PCa were treated with IMAT and 2-3 years of AD. A median dose of 69.3 Gy (normalized isoeffective dose at 2 Gy per fraction: 80 Gy [α/β = 3]) was prescribed in 25 fractions to the prostate. The pelvic lymph nodes received a minimal dose of 45 Gy. A simultaneous integrated boost to 72 Gy and 65 Gy was delivered to the intraprostatic lesion and/or pathologically enlarged lymph nodes, respectively. GI and GU toxicity was scored using the RTOG/RILIT and RTOG-SOMA/LENT-CTC toxicity scoring system respectively. Three-year actuarial risk of grade 2 and 3/4 GI-GU toxicity and biochemical and clinical relapse free survival (bRFS and cRFS) were calculated with Kaplan-Meier statistics. Results Median follow-up was 36 months. Three-year actuarial risk for late grade 3 and 2 GI toxicity is 8% and 20%, respectively. Three-year actuarial risk for late grade 3-4 and 2 GU toxicity was 6% and 34%, respectively. Actuarial 3-year bRFS and cRFS was 81% and 89%, respectively. Actuarial 3-year bRFS and cRFS was, respectively 26% and 32% lower for patients with cN1 disease when compared to patients with cN0 disease. Conclusion IMAT for N1 PCa offers good clinical outcome with moderate toxicity. Patients with cN1 disease have poorer outcome.
机译：背景和目的对于N1前列腺癌（PCa）患者，可以提倡积极的局部治疗。我们评估了N1 PCa的调强电弧放疗（IMAT）+雄激素剥夺（AD）后的临床结局，胃肠道（GI）和生殖泌尿（GU）毒性。材料和方法80例T1-4N1M0 PCa患者接受了IMAT和2-3年的AD治疗。在前列腺的25个部位开出了69.3 Gy的中位剂量（每级2 Gy的标准化等效剂量：80 Gy [α/β= 3]）。盆腔淋巴结的最小剂量为45 Gy。同时向前列腺内病变和/或病理上扩大的淋巴结传递了同时达到72 Gy和65 Gy的综合增强。 GI和GU毒性分别使用RTOG / RILIT和RTOG-SOMA / LENT-CTC毒性评分系统进行评分。使用Kaplan-Meier统计数据计算2级和3/4 GI-GU毒性以及生化和临床无复发生存期（bRFS和cRFS）的三年精算风险。结果中位随访时间为36个月。晚期3级和2级胃肠道毒性的三年精算风险分别为8％和20％。晚期3-4级和2 GU毒性的三年精算风险分别为6％和34％。精算3年期bRFS和cRFS分别为81％和89％。与cN0病患者相比，cN1病患者精算3年期bRFS和cRFS分别降低26％和32％。结论IMAT用于N1 PCa具有良好的临床疗效，且毒性中等。 cN1病患者的预后较差。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号